JP2017533182A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017533182A5 JP2017533182A5 JP2017514626A JP2017514626A JP2017533182A5 JP 2017533182 A5 JP2017533182 A5 JP 2017533182A5 JP 2017514626 A JP2017514626 A JP 2017514626A JP 2017514626 A JP2017514626 A JP 2017514626A JP 2017533182 A5 JP2017533182 A5 JP 2017533182A5
- Authority
- JP
- Japan
- Prior art keywords
- tdo
- seq
- peptide fragment
- vaccine composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201470571 | 2014-09-17 | ||
| DKPA201470571 | 2014-09-17 | ||
| PCT/DK2015/050274 WO2016041560A1 (en) | 2014-09-17 | 2015-09-15 | Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017533182A JP2017533182A (ja) | 2017-11-09 |
| JP2017533182A5 true JP2017533182A5 (enExample) | 2018-10-25 |
| JP6811710B2 JP6811710B2 (ja) | 2021-01-20 |
Family
ID=51661826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017514626A Active JP6811710B2 (ja) | 2014-09-17 | 2015-09-15 | トリプトファン２，３−ジオキシゲナーゼまたはそのフラグメントを含むワクチン組成物 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10736950B2 (enExample) |
| EP (2) | EP3193917B9 (enExample) |
| JP (1) | JP6811710B2 (enExample) |
| CN (1) | CN106999557B (enExample) |
| AU (1) | AU2015317446B2 (enExample) |
| CA (1) | CA2959197C (enExample) |
| CY (1) | CY1124738T1 (enExample) |
| DK (1) | DK3193917T3 (enExample) |
| ES (1) | ES2891902T3 (enExample) |
| HR (1) | HRP20211540T2 (enExample) |
| HU (1) | HUE056414T2 (enExample) |
| IL (1) | IL251101B (enExample) |
| LT (1) | LT3193917T (enExample) |
| PL (1) | PL3193917T3 (enExample) |
| PT (1) | PT3193917T (enExample) |
| SI (1) | SI3193917T1 (enExample) |
| WO (1) | WO2016041560A1 (enExample) |
| ZA (1) | ZA201701179B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110628736B (zh) * | 2019-10-09 | 2021-05-11 | 扬州大学 | 色氨酸2,3双加氧酶突变体及其制备方法和应用 |
| CN111012919B (zh) * | 2019-12-23 | 2021-06-01 | 山东大学 | 聚乙二醇化的icd诱导剂-ido抑制剂纳米缀合物及制备方法与应用 |
| CN111803635B (zh) * | 2020-06-17 | 2023-03-14 | 中国医学科学院基础医学研究所 | 小分子抑制剂在治疗呼吸道病毒性肺炎上的应用 |
| EP4340948A4 (en) * | 2021-05-17 | 2025-03-12 | Wisconsin Alumni Research Foundation (WARF) | SYNTHETIC PROTEIN TO INDUCE IMMUNE TOLERANCE |
| WO2023161350A1 (en) | 2022-02-24 | 2023-08-31 | Io Biotech Aps | Nucleotide delivery of cancer therapy |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US58767A (en) | 1866-10-16 | John brougjbton | ||
| US5554372A (en) | 1986-09-22 | 1996-09-10 | Emory University | Methods and vaccines comprising surface-active copolymers |
| US5840839A (en) * | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
| US6096313A (en) | 1996-02-09 | 2000-08-01 | Ludwig Institute For Cancer Research | Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant |
| EP1522594A3 (en) * | 2003-10-06 | 2005-06-22 | Bayer HealthCare AG | Methods and kits for investigating cancer |
| DE102004039196B4 (de) * | 2004-08-12 | 2008-07-31 | Dr.Kamprad Kg | Neue Formulierung für L-Tryptophan |
| US20110159017A1 (en) * | 2008-04-11 | 2011-06-30 | Ludwig Institute For Cancer Research Ltd. | Trytophan catabolism in cancer treatment and diagnosis |
| US9433666B2 (en) * | 2008-04-17 | 2016-09-06 | IO Bioech ApS | Indoleamine 2,3-dioxygenase based immunotherapy |
| CA3197245A1 (en) * | 2010-05-14 | 2011-11-17 | The General Hospital Corporation | Compositions and methods of identifying tumor specific neoantigens |
| CA2850245C (en) | 2011-10-17 | 2020-04-28 | Herlev Hospital | Pd-l1 based immunotherapy |
| GB201120860D0 (en) * | 2011-12-05 | 2012-01-18 | Cambridge Entpr Ltd | Cancer immunotherapy |
-
2015
- 2015-09-15 EP EP15774851.8A patent/EP3193917B9/en active Active
- 2015-09-15 ES ES15774851T patent/ES2891902T3/es active Active
- 2015-09-15 CA CA2959197A patent/CA2959197C/en active Active
- 2015-09-15 LT LTEPPCT/DK2015/050274T patent/LT3193917T/lt unknown
- 2015-09-15 JP JP2017514626A patent/JP6811710B2/ja active Active
- 2015-09-15 HU HUE15774851A patent/HUE056414T2/hu unknown
- 2015-09-15 EP EP21176526.8A patent/EP3919074A1/en active Pending
- 2015-09-15 HR HRP20211540TT patent/HRP20211540T2/hr unknown
- 2015-09-15 PT PT157748518T patent/PT3193917T/pt unknown
- 2015-09-15 US US15/509,443 patent/US10736950B2/en active Active
- 2015-09-15 AU AU2015317446A patent/AU2015317446B2/en active Active
- 2015-09-15 WO PCT/DK2015/050274 patent/WO2016041560A1/en not_active Ceased
- 2015-09-15 CN CN201580050212.3A patent/CN106999557B/zh active Active
- 2015-09-15 DK DK15774851.8T patent/DK3193917T3/da active
- 2015-09-15 PL PL15774851T patent/PL3193917T3/pl unknown
- 2015-09-15 SI SI201531744T patent/SI3193917T1/sl unknown
-
2017
- 2017-02-16 ZA ZA2017/01179A patent/ZA201701179B/en unknown
- 2017-03-12 IL IL251101A patent/IL251101B/en active IP Right Grant
-
2020
- 2020-07-07 US US16/922,604 patent/US11878053B2/en active Active
-
2021
- 2021-11-16 CY CY20211100992T patent/CY1124738T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017533182A5 (enExample) | ||
| ES2816630T3 (es) | Composiciones de flagelina y usos | |
| ES2675020T3 (es) | Vectores basados en Salmonella para inmunoterapia del cáncer dirigida al gen WT1 del tumor de Wilms | |
| JP2016501829A5 (enExample) | ||
| JP2010166916A5 (enExample) | ||
| JP2017538401A5 (enExample) | ||
| JP2009292810A5 (enExample) | ||
| EP2573110A3 (en) | Peptide vaccines with Seq Id No: 174, 178, 186 or 194 for cancers expressing tumor-associated antigens | |
| JP2016521688A5 (enExample) | ||
| WO2016107818A8 (en) | Compositions and methods for protein glycosylation | |
| JP2019537562A5 (enExample) | ||
| JP2017529326A5 (enExample) | ||
| FI3522905T3 (fi) | Immunogeenisiä arginaasipeptidejä | |
| RU2017127012A (ru) | IL-17A-связанные полипептиды | |
| JP2019517544A5 (enExample) | ||
| US20240026317A1 (en) | PAN-RAS mRNA CANCER VACCINES | |
| JP2015522264A5 (enExample) | ||
| HRP20211540T1 (hr) | Sastavi cjepiva koji sadrže triptofan 2,3-dioksigenazu ili njene fragmente | |
| JP2012102105A5 (enExample) | ||
| HRP20130022T1 (hr) | Fuzijski proteini koji sadrže antigene ny-eso-1 i lage-1 za odbacivanje tumora | |
| JP2015514115A5 (enExample) | ||
| PH12014500720A1 (en) | Topk peptides and vaccines including the same | |
| JP2018532763A5 (enExample) | ||
| JP2013542942A5 (enExample) | ||
| JP2017519763A5 (enExample) |